<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02443103</url>
  </required_header>
  <id_info>
    <org_study_id>IUCRO-0506</org_study_id>
    <nct_id>NCT02443103</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis</brief_title>
  <official_title>Exploratory Pilot Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kathy Miller</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will explore the biologic activity of guanabenz in reducing bone turn over in
      solid tumor patients with bone metastasis. If successful, this repurposing of an already,
      generic drug could benefit patients faster than manufacturing a novel expensive compound.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES Primary Objective: Evaluate the biologic effect of guanabenz on markers of bone
      formation and bone resorption in patients with solid tumors and bone metastasis.

      Secondary Objectives: (1) Compare guanabenz exposure in patients based on limited PK sampling
      to activity observed in previous pre-clinical studies; (2) Assess the safety/tolerability of
      guanabenz; and (3) Evaluate the biologic effect of guanabenz on bone metabolism markers.

      Tertiary Objective: Compare change in bone turn over markers (formation, resorption and
      metabolism) achieved with guanabenz to change in bone turn over markers with standard of care
      (bisphosphonate/denosumab).

      STUDY DESIGN This is an exploratory pilot study evaluating the biologic effect of guanabenz
      bone formation and bone resorption markers in patients with solid tumors and bone metastasis.

      PROCEDURES All registered patients will receive oral guanabenz the first two months prior to
      the start of any standard of care skeletal protective therapy. All patients on study will
      receive standard of care systemic treatment for their underlying solid malignancy as deemed
      necessary by their treating physician. Guanabenz will be administered concurrently with any
      primary cancer systemic treatment. However patients will withhold standard of care bone
      directed therapy for 8 weeks. The study will exclude patients in immediate need of such
      treatment. Patients experiencing skeletal related events while on study will be withdrawn.
      Delaying standard of care skeletal therapy for 2 months will not be considered a major
      deviation as long as such therapy is delayed for a necessary purpose as deemed by the
      treating physician.

      Patients with known hypertension and on antihypertensive medications at study enrollment will
      be eligible to participate. Antihypertensive medications will not be changed as a result of
      study enrollment unless deemed necessary by the treating physician; only the dose of
      guanabenz will be adjusted.

      TREATMENT Patients will begin taking 8 mg by mouth (PO) at bed time (HS) starting day 1 for
      one week. The dose will be increased to 8 mg PO twice a day (BID) (8 mg daily morning (QAM)
      and 8 mg daily evening (QPM) for a total of 16 mg) on day 8 (+/-3 days), then increased to 8
      mg PO QAM 16 mg PO QPM (total of 24 mg) on day 15 (+/- 3 days), then increased to 16 mg PO
      BID (16 mg QAM and 16 mg QPM for a total of 32 mg) on day 22. Patients will continue on their
      maximum tolerated dose (MTD) until day 56 (+/- 3 days). The dose will be weaned for patients
      receiving more than 8 mg daily after completing week 8 when the standard of care skeletal
      protective therapy begins. Guanabenz will be weaned off by week 11, and patients will
      continue standard of care skeletal protective therapy as deemed necessary by the treating
      physician.

      To ensure patient safety during dose escalation and throughout the study, patients will be
      provided and taught the use of home blood pressure (BP) monitoring. We will instruct patients
      to check their BP 2 hours after each guanabenz dose escalation and at least three times
      weekly. Patients will maintain a diary of BP results during the dose escalation phase.
      Patients will report any hypotensive measurement to their research nurse defined as at least
      two readings less than &lt; 100/60 mm Hg in sitting position taken more than 30 min apart.

      At each visit, blood pressure and adverse events will be assessed. Dose escalation will
      continue with guanabenz if BP &gt;= 110/70 mm Hg and/or until unacceptable toxicity.

      Guanabenz should be taken as instructed on an empty stomach. If the patient misses a dose of
      guanabenz, he/she can take the missing dose no later than 3 hours after instructed time and
      then continue as scheduled.

      On day 57 (+/- 3 days), all study patients start the guanabenz wean. All patients will
      receive ongoing standard of care skeletal protective therapy (denosumab/zometa) as determined
      by the treating physician at the beginning of the weaning phase.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual
  </why_stopped>
  <start_date type="Actual">May 7, 2015</start_date>
  <completion_date type="Actual">June 8, 2016</completion_date>
  <primary_completion_date type="Actual">June 8, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Turnover Markers-bone Formation and Bone Resorption</measure>
    <time_frame>Day 0, Week 8, Week 12</time_frame>
    <description>Number of patients who had blood specimens taken to collect and evaluate markers of bone formation and bone resorption. Note - due to poor accrual and early closure, bone marker data was not collected.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment Related Adverse Events</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Number of unique patients who had a treatment related (possible, probable or definite) adverse events.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Bone Cancer</condition>
  <condition>Metastasis</condition>
  <arm_group>
    <arm_group_label>Guanabenz</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guanabenz acetate</intervention_name>
    <arm_group_label>Guanabenz</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. â‰¥ 18 years old at the time of informed consent

          2. Ability to provide written informed consent and HIPAA authorization

          3. Solid organ malignancy with documented bone metastasis by imaging

          4. Adequate liver function (serum total bilirubin &lt;= 3 and AST/ALT &lt;= 3 times the upper
             normal limit)

          5. Adequate renal function (serum creatinine &lt;= 2mg/dL)

          6. Ability to swallow oral tablets

          7. Females of childbearing potential must have a negative pregnancy test &lt;= 28 days prior
             to registration. All females of childbearing potential who are sexually active, must
             agree to use a highly reliable method of contraception to prevent pregnancy. These
             include abstinence, partner with previous vasectomy, placement of an intrauterine
             device (IUD), condom with spermicidal foam/gel/film/cream/suppository, diaphragm or
             cervical vault cap, or hormonal birth control (pills or injections).

             NOTE: Females are considered of childbearing potential unless they are surgically
             sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral
             oophorectomy) or they are postmenopausal (&gt; 12 months since last menses).

          8. Patients are permitted to participate in other clinical trials while participating in
             this trial.

          9. Patients will receive standard of care systemic treatment for underlying solid
             malignancy as deemed necessary by treating physician.

        Exclusion Criteria:

          1. No prior history of bisphosphonate ordenosumab use in the past 12 months

          2. No history of SRE within past 3 months

               1. Excruciating bone pain requiring RT

               2. Cord compression

               3. Hypercalcemia [serum calcium &gt;10.5]

               4. Pathologic fracture

          3. No history of Paget's disease

          4. No history of epilepsy/seizures

          5. No history of hypotension (defined as resting systolic blood pressure of &lt; 110 mm Hg
             or diastolic blood pressure of &lt; 70 mm Hg) or orthostasis (defined as drop in systolic
             blood pressure of &gt;20 mm Hg or increase in HR of &gt; 20 from supine to standing
             position).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathy Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University (IU) School of Medicine, Department of Medicine; IU Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Health Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney &amp; Lois Eskenazi Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spring Mill Medical Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2015</study_first_submitted>
  <study_first_submitted_qc>May 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2015</study_first_posted>
  <results_first_submitted>August 17, 2017</results_first_submitted>
  <results_first_submitted_qc>February 8, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 13, 2018</results_first_posted>
  <last_update_submitted>February 8, 2018</last_update_submitted>
  <last_update_submitted_qc>February 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University School of Medicine</investigator_affiliation>
    <investigator_full_name>Kathy Miller</investigator_full_name>
    <investigator_title>Full Professor of Medicine and Sheila D. Ward Scholar</investigator_title>
  </responsible_party>
  <keyword>pilot study</keyword>
  <keyword>guanabenz acetate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Guanabenz</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This protocol was based on enrolling 15 patients. Due to poor accrual and the decision that the approach with this agent is not feasible, the study was closed with 4 patients enrolled.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Guanabenz</title>
          <description>Guanabenz (titrate up from 8mg PO QPM to 16mg PO BID max dose)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Guanabenz</title>
          <description>Guanabenz (titrate up from 8mg PO QPM to 16mg PO BID max dose)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.6" spread="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bone Turnover Markers-bone Formation and Bone Resorption</title>
        <description>Number of patients who had blood specimens taken to collect and evaluate markers of bone formation and bone resorption. Note - due to poor accrual and early closure, bone marker data was not collected.</description>
        <time_frame>Day 0, Week 8, Week 12</time_frame>
        <population>All patients receiving at least one dose of study drug and having at least one evaluable post-baseline visit with bone marker information available.</population>
        <group_list>
          <group group_id="O1">
            <title>Guanabenz</title>
            <description>Guanabenz (titrate up from 8mg PO QPM to 16mg PO BID max dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Turnover Markers-bone Formation and Bone Resorption</title>
          <description>Number of patients who had blood specimens taken to collect and evaluate markers of bone formation and bone resorption. Note - due to poor accrual and early closure, bone marker data was not collected.</description>
          <population>All patients receiving at least one dose of study drug and having at least one evaluable post-baseline visit with bone marker information available.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Related Adverse Events</title>
        <description>Number of unique patients who had a treatment related (possible, probable or definite) adverse events.</description>
        <time_frame>Up to 1 year</time_frame>
        <population>All patients enrolled and received treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Guanabenz</title>
            <description>Guanabenz (titrate up from 8mg PO QPM to 16mg PO BID max dose)</description>
          </group>
        </group_list>
        <measure>
          <title>Treatment Related Adverse Events</title>
          <description>Number of unique patients who had a treatment related (possible, probable or definite) adverse events.</description>
          <population>All patients enrolled and received treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Guanabenz</title>
          <description>Guanabenz (titrate up from 8mg PO QPM to 16mg PO BID max dose)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to poor accrual and the early closure, results were not obtained for the bone marker and pharmacokinetics analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Kathy Miller</name_or_title>
      <organization>IndianaU</organization>
      <phone>317-948-3855</phone>
      <email>kathmill@iu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

